Journal ArticleDOI
nanoparticle albumin-bound paclitaxel: a novel Cremphor-el®-free formulation of paclitaxel
TLDR
The preclinical and clinical data indicate that the nab-paclitaxel formulation has significant advantages over Cremphor-EL-pac litaxel, including a shorter infusion time and no need for premedications for hypersensitivity reactions.About:
This article is published in Nanomedicine: Nanotechnology, Biology and Medicine.The article was published on 2007-08-23. It has received 176 citations till now. The article focuses on the topics: Taxane & Paclitaxel.read more
Citations
More filters
Journal ArticleDOI
Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
TL;DR: Suitable formulations for the most commonly used routes of administration can be identified with milligram quantities of drug substance providing the discovery scientist an alternate avenue for screening and identifying superior leads.
Journal ArticleDOI
Managing diabetes with nanomedicine: challenges and opportunities
TL;DR: The current state of nanotechnology-based approaches for improving the care of patients with diabetes is analyzed and key issues for their translation to clinical practice are discussed.
Journal ArticleDOI
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ping Ma,Russell J. Mumper +1 more
TL;DR: In this comprehensive review, several types of developed paclitaxel nano-delivery systems will be covered and discussed, such as polymeric nanoparticles, lipid-based formulations, polymer conjugates, inorganic nanoparticles), carbon nanotubes, nanocrystals, and cyclodextrin nanoparticles.
Journal ArticleDOI
Clinical Cancer Nanomedicine.
Joy Wolfram,Mauro Ferrari +1 more
TL;DR: Successful clinically approved cancer nanodrugs as well as promising candidates in the pipeline are discussed, categorized according to whether they predominantly exploit multifunctionality, unique electromagnetic properties, or distinct transport characteristics in the body.
References
More filters
Journal ArticleDOI
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H. Schiller,David P. Harrington,Chandra P. Belani,Corey J. Langer,Alan B. Sandler,James E. Krook,Junming Zhu,David H. Johnson +7 more
TL;DR: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
J Oan H. S Chiller,D Avid H Arrington,C Handra P. B Elani,C Orey L Anger,A Lan S Andler,J Ames K Rook,J Unming Z Hu,D Avid H. J Ohnson +7 more
TL;DR: The response rate for all 1155 eligible pa-tients was 19 percent, with a median survival of 79 months (95 percent confidence interval, 73 to 85), a1-year survival rate of 33 percent, and a 2-year surviv-al rate of 11 percent.
Journal ArticleDOI
Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.
Journal ArticleDOI
Promotion of microtubule assembly in vitro by taxol
TL;DR: It is reported here that taxol acts as a promoter of calf brain microtubule assembly in vitro, in contrast to plant products such as colchicine and podophyllotoxin, which inhibit assembly.
Journal ArticleDOI
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Robert F. Ozols,Brian N. Bundy,Benjamin E. Greer,Jeffrey M. Fowler,Daniel L. Clarke-Pearson,Robert A. Burger,Robert S. Mannel,Koen DeGeest,Ellen M. Hartenbach,Rebecca N. Baergen +9 more
TL;DR: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin pluspaclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus pac Litaxel.